BACKGROUND: Because environmental insults and genetic factors account for the variance in the risk of bronchopulmonary dysplasia (BPD) in very low birth weight (VLBW, birth weight < 1,500 g) preterm infants, the search for BPD biomarkers has begun to focus on the regulators of non-coding RNA such as microRNAs (miRNAs). Therefore, this study aimed to identify potential miRNAs involved in the pathogenesis of BPD in VLBW preterm infants. METHODS: A case-control study (15 subjects with BPD and 15 sex-matched control subjects without BPD) was conducted to investigate the expression profiles of 365 miRNAs in the peripheral blood of VLBW preterm infants at 36 weeks post-menstrual age (called the older-age set). The expression levels of identified miRNAs were further evaluated in a subsample of blood collected during the first 2 weeks post-natal age (called the younger-age set). Possible biological functions and pathways implicated in the target genes regulated by the miRNAs were explored using database predictions. RESULTS: A 4-miRNA signature (miR-152, miR-30a-3p, miR-133b, and miR-7) with aberrant expression levels at 36 weeks, derived from a supervised classification with internal cross-validation, discriminated the subjects with BPD from those without BPD with an accuracy of 0.91. The discriminative accuracy of the 4 miRNAs was supported by random permutations of either the disease status or the number of miRNAs selected (both P < .001). A down-regulation change of miR-152 and miR-30a-3p expression levels and an up-regulation change of miR-133b and miR-7 expression levels were found in the older-age set, compared to the younger-age set. CONCLUSIONS: This is the first study to identify blood-based miRNAs associated with BPD. The findings provide information regarding the roles of these biomarkers in the development of BPD in VLBW preterm infants.
Introduction
Bronchopulmonary dysplasia (BPD) is an important chronic lung disease in preterm infants with very low birth weight (VLBW, birth weight Ͻ 1,500 g). 1, 2 Recent advances in the prevention and management of this respiratory illness, such as antenatal steroid treatment, exogenous surfactant therapy, and gentle ventilator strategies, have changed the underlying pathology of BPD from severe structural disruption to developmental arrest of the neonatal lung. [3] [4] [5] The new form of BPD frequently occurs in extremely preterm infants with pathological features, including impaired alveolarization, vascular growth abnormalities, and mild inflammation. 5, 6 In addition to environmental insults (eg, hyperoxia exposure and respiratory therapies) to the immature lung in preterm infants, genetic factors may also account for a portion of the variation in BPD. 7, 8 Although several association studies have examined the roles of genetic variants in inflammatory regulation and surfactant synthesis in BPD, the results have failed to show consistent associations. [9] [10] [11] [12] [13] [14] [15] [16] [17] In developmentally appropriate BPD animal models, altered expression levels of certain transcription factors for protein-coding RNA have been linked to alveolarization, angiogenesis, or remodeling of the lung extracellular matrix. [18] [19] [20] [21] [22] However, BPD pathogenesis in human infants remains incompletely understood.
Instead of targeting DNA or protein-coding RNA in BPD, recent advances in molecular genetics have provided a new strategy for understanding the post-transcriptional regulation of gene expression via non-coding RNAs, in particular microRNAs (miRNAs), which have a regulatory effect on the translation of messenger RNA and protein production. 23 To date, approximately 1,600 human miRNAs have been identified and sequenced. 24 Approximately 30% of messenger RNAs are targeted by miRNAs, and aberrant expression of miRNAs can lead to many disease states. 25, 26 Although recent animal studies have identified several miRNAs in the developmental process of the embryonic lung, and alterations in miRNA expression profiles are associated with BPD, [27] [28] [29] [30] [31] information regarding the role of miRNAs in BPD in human infants is limited.
This study, therefore, aimed to investigate miRNA expression levels in the peripheral blood of VLBW preterm infants with BPD and sex-matched controls at 36 weeks post-menstrual age (called the older-age set). The expression levels of the differentially expressed miRNAs was further examined in a subsample of blood collected during the first 2 weeks post-natal age (called the younger-age set) to elucidate the evolution of miRNA expression during BPD development. The possible functions and biological mechanisms implicated by the target genes regulated by these miRNAs were also explored using database prediction.
Methods
This study was approved by the ethics committees of the participating hospitals. Written informed consent was obtained from the father or mother after a complete description of the study.
Subjects
From September 2008 to December 2009, we prospectively enrolled VLBW preterm infants who were admitted to the neonatal ICU at the National Taiwan University Hospital and Mackey Memorial Hospital in Taipei, Taiwan. The recruitment was conducted during the first postnatal week. The inclusion criteria included gestational age Ͻ 33 weeks, birth weight Ͻ 1,500 g, absence of congenital and chromosomal abnormalities, and born in or admitted to the neonatal ICU within 7 days of birth. Patients were excluded if their parents were of non-Taiwanese ethnicity, maternal age was Ͻ 18 years, or there was a maternal history of substance abuse or psychiatric disorder. BPD was graded for its severity at 36 weeks post-menstrual age, according to the consensus definition of the United States National Institutes of Health. 3 Of the 54 eligible VLBW preterm infants, 53 (98%) participated, and 1 (2%) refused to participate in this study. After enrollment, 50 infants survived to 36 weeks postmenstrual age; 20 had BPD and 30 did not. The incidence rate of BPD in our infants (37%) was comparable to that reported by the participating hospitals (20 -40%). We collected 500 l of arterial blood twice from each subject, in conjunction with routine daily blood tests. The first blood draw was scheduled during the first 2 weeks of post-natal age (called the younger-age set), and the second blood draw was conducted at 36 weeks post-menstrual age (called the older-age set).
The perinatal and demographic data of the VLBW preterm infants were obtained from the infants' medical charts or via parental interview during hospitalization. The perinatal data included birth variables, respiratory variables,
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Current knowledge
Bronchopulmonary dysplasia (BPD) is a chronic lung disease in preterm infants with very low birth weight. Recent advances in prevention and management of BPD have changed the underlying pathology to a syndrome including impaired alveolarization, vascular growth abnormalities, and mild inflammation.
What this paper contributes to our knowledge Down-regulation of 2 microRNAs (miR-152 and miR-30a-3p), and up-regulation of 2 others (miR-133b and miR-7), were found in peripheral blood samples from very low birth weight infants. Those 4 miRNAs and the related target genes provide insight for future investigation of the pathogenesis of BPD. and neonatal morbidities. The birth variables included sex, gestational age, birth weight, and birth set. The respiratory variables included the duration of ventilation and CPAP use. The neonatal morbidities included intraventricular hemorrhage, periventricular leukomalacia, patent ductus arteriosus, retinopathy of prematurity, necrotizing enterocolitis, and sepsis. The demographic data included sex and maternal education and occupation.
RNA Extraction and MicroRNA Quantification
Approximately 2-4 g of RNA from mononuclear leukocyte was extracted from each blood sample (RiboPure blood kit, Applied Biosystems/Life Technologies, Carlsbad, California). The RNAs of the older-age set were assayed for the expression of 365 human miRNAs (Multiplex RT and TaqMan low density array human microRNA panel v1.0, and 7900 real-time RT-PCR system, Applied Biosystems/Life Technologies, Carlsbad, California), using RNU48 as an endogenous control. The RNAs of the younger-age set were quantified using the qRT-PCR for the expression levels of the individual miRNAs identified from the older-age set.
The expression level of each miRNA from the arraybased profiling was quantified through the normalized threshold cycle number (⌬C t ), in which
and the relative expression level was calculated as 2 Ϫ(⌬C t ), which is commonly used in genome-wide miRNA profiling studies. 32 The fold-change in the expression of miRNA between 2 groups was calculated as 2 Ϫ(⌬⌬C t ).
Statistical Analyses
For group comparisons of perinatal and demographic variables between the VLBW preterm infants with versus without BPD, the Fisher exact test was used for categorical variables, and the Wilcoxon signed rank test was used for continuous variables. Significant variables were considered as potential confounders for subsequent analyses of the relationship of miRNA expression levels to BPD occurrence.
To select differentially expressed miRNAs from the older-age set, the Wilcoxon rank-sum test was used to compare the continuous data of expression levels, and the Fisher exact test to compare the binary data of detectability between groups, based on a liberal threshold P of 0.2. The markers identified from univariate analyses were then subjected to the stepwise logistic regression analysis to select a cluster of miRNAs that could discriminate the subjects with BPD from those without BPD. Furthermore, the leaveone-out cross-validation and 2 types of permutations (permutation of disease status and number of markers selected) were conducted to evaluate the robustness of discrimination by the identified miRNA signature. 33 Subsequently, the fold-change in the relative expression of miRNA and the direction of fold-change from the younger-age set to the older-age set were examined in the subsample with RNAs available at both time points.
The potential target genes regulated by the miRNAs were assessed using the miRWALK algorithm. 34 The software Ingenuity Pathways Analysis (IPA, Ingenuity Systems, Redwood City, California), which contains global molecular network data, was used to explore the biological and functional pathway for the target genes. All statistical analyses were performed with statistics software (SAS 9.1, SAS Institute, Cary, North Carolina), and a P value of Ͻ .05 was considered significant.
Results
Sample Characteristics
Of the 50 subjects, the first blood draw was successfully conducted in 21: 11 subjects with BPD (10 with moderate BPD and 1 with severe BPD) and 10 control subjects without BPD, within the first 2 post-natal weeks to form the younger-age set ( Table 1 ). The second blood draw was successfully performed in 44 subjects at 36 weeks postmenstrual age. Fifteen subjects with BPD (14 with moderate BPD and 1 with severe BPD) and 15 sex-matched control subjects without BPD were selected to form the older-age set. In both sets, the subjects with BPD had younger gestational ages and lower birth weights and required longer ventilation and CPAP use than did the subjects without BPD (all P Ͻ .05). Furthermore, the subjects with BPD were more likely to have patent ductus arteriosus (both P Ͻ .05). Analysis of the respiratory data between the subjects with BPD and a subgroup of subjects without BPD (n ϭ 10) with comparable gestational ages (Ͻ 31 weeks) indicated a longer use of ventilation and CPAP in the former than in the latter (all P Ͻ .05, data not shown).
miRNAs Identified From the Older-Age Set
For the older-age set, the blood samples tended to be collected earlier for the subjects with BPD than for the subjects without BPD (post-natal age 37 Ϯ 11 d vs 47 Ϯ 12 d), although the difference did not reach significance (P ϭ .09). Of the 365 miRNAs examined in the older-age set, 210 (58%) were detected in the infants, and 155 (42%) were undetectable. The heat maps of 365 miRNAs in terms of the proportion of infants in each group with detectable expression are illustrated in Figure 1 , using the Generalized Association Plots program. 35 For 210 detectable miRNAs, the expression levels did not differ between the subjects with versus without BPD. When miRNA expression was dichotomized as detectable or not, differential detectability between groups was found in 4 miRNAs. The stepwise logistic regression analysis revealed that miR-133b and miR-7 had significantly higher detectability in the subjects with BPD than in those without, whereas miR-152 and miR-30a-3p had significantly lower detectability in the subjects with BPD (all P Ͻ .05, Table 2 ).
The utility of these 4 miRNAs in discriminating the subjects with BPD from those without was evaluated using multivariable logistic regression analysis, with a leaveone-out cross-validation procedure. The 4-miRNA signature was associated with the greatest accuracy value, with an area under the curve of the receiver operating characteristic of 0.91 (Fig. 2) . The sensitivity and specificity for the optimal combination of the 4 miRNAs (expression of miR-133b and miR-7 together with non-expression of miR-152 and miR-30a-3p) were 0.87 and 0.80, respectively. Because there were high correlations among potential confounding perinatal variables, only some were included as covariates in the analysis. After adjustment for the effect of birth weight and patent ductus arteriosus, the specificity slightly increased, to 0.87, and the sensitivity remained unchanged.
The robustness of BPD discrimination by the 4-miRNA signature was further evaluated using permutations, in 2 ways. First, when the disease status of the subjects was permuted 100,000 times, none of the areas under the curve derived from the permuted samples (mean Ϯ SD 0.63 Ϯ 0.07) exceeded the observed value of 0.91 (P Ͻ .001). Second, when a certain number of miRNAs (range 3-9) were randomly selected, the average of areas under the curve (range 0.44 -0.73) was found to be smaller than those observed for the 4-miRNA signature.
Expression of 4 MicroRNAs in the Younger-Age and Older-Age Sets
For the 16 infants (7 subjects with BPD and 9 subjects without BPD) whose RNA expression levels were available in both the younger-age and older-age sets, the fold change in the expression levels of the 4 miRNAs were compared (Fig. 3) . For the younger-age set, the fold change in the expression levels between the BPD and the non-BPD group was positive for miR-152 and negative for miR-30a-3p, miR-133b, and miR-7. For the older-age set, the fold change in the expression levels was negative for miR-152 and miR-30a-3p and positive for miR-133b and 
Target Genes and Functional Relevance of the 4-miRNA Signature
Of the 4 miRNAs, miR-152, miR-30a-3p, and miR-7 are included in the human database miRNAMap with detectable expression in lung tissue. 36 The miRWALK algorithm indicated that 7,239 target genes were relevant to the 4 miRNAs, with 66 being shared target genes. The functional pathway analysis showed that the shared target genes may be related to organ and embryonic development as well as developmental disorders (all P Ͻ .001, Table 3 ). Among them, GLI3 and NFIB were the most significant target genes involved in lung development (both P Ͻ .001). Canonical biological pathway analysis revealed that the pathways with the most significant changes were the Wnt/ ␤-catenin and axon guidance signaling pathways (both P ϭ .04).
Discussion
To our knowledge, this is the first study to investigate the peripheral blood of VLBW preterm infants in early post-natal life for differentially expressed miRNAs that have an association with BPD. We identified 4 miRNAs with expression levels at 36 weeks post-menstrual age that differed between VLBW preterm infants with and without BPD. Two time-point comparisons of the expression levels of these miRNAs, at 36 weeks post-menstrual age with those at the first 2 weeks post-natal age, further revealed a down-regulation change in miR-152 and miR-30a-3p expression, together with an up-regulation change in miR133b and miR-7 expression during the early stage of BPD. Our results provide a preliminary understanding of the roles of miRNAs in the development of BPD in VLBW preterm infants.
The 4-miRNA signature had acceptable discriminative value for the detection of BPD in VLBW preterm infants. Our observation concerning the higher discriminative accuracy of the combined altered expressions of these 4 miRNAs than that of a single miRNA was consistent with the findings of a previous study. 33 Because miRNAs are regulators closer in temporal sequence to outcome than is genetic information encoded in the genome, the aberrantly expressed miRNAs may be useful biomarkers for BPD. Among the 4 differentially expressed miRNAs, miR-30a-3p and miR-30 were highly up-regulated in mouse lung during the period of lung septation. 27, 31 In humans, miR-30a- Fig. 1 . MicroRNA (miRNA) expression profiling of 365 miRNAs in very low birth weight preterm infants of the older-age set, with and without bronchopulmonary dysplasia (BPD). The heat maps of individual miRNAs for each group are presented as the proportion of infants with detectable miRNA expression, with higher proportions (more red in color) indicating more infants showing expression. Two miRNAs (miR-7 and miR-133b) showed higher expression levels (more red in color), and the others (miR-152 and miR-30a-3p) showed lower expression levels (more green in color) in the BPD group.
3p, miR-133b, and miR-7 are associated with adult lung diseases, with miR-30a-3p and miR-133b being downregulated and miR-7 being up-regulated in lung tumor tissue of adults with adenocarcinoma. [37] [38] [39] Furthermore, miR-152 is associated with childhood asthma. 40 Thus, these 4 miRNAs appear to be associated with a variety of lung diseases.
BPD in preterm infants has been postulated to result from lung injuries related to prolonged use of ventilation and oxygen therapy in the neonatal period. 3, 5, 6 In this study preterm infants with BPD had longer ventilation duration (median 7 d vs 0 d) and CPAP use (median 34 d vs 4 d) than those without BPD. Furthermore, the 4 miRNAs showed different expression levels in the peripheral blood of preterm infants with BPD at 36 weeks post-menstrual age when respiratory support was in use. A study in humans found that hypoxic events altered the expression of several miRNAs (eg, miR-152) in colonic cells. 41 An animal study screening for lung miRNA profiles in rats after chronic hypoxia showed aberrant expression of several miRNA markers, including miR-30. 42 It is possible that the aberrant expression of miRNAs might relate to hypoxic or hyperoxic insults from ventilator and oxygen use.
It is noteworthy that our preliminary results suggest a developmental shift in the expression pattern of these 4 miRNAs (ie, down-regulation of miR-152 and miR-30a-3p and up-regulation of miR-133b and miR-7) during the neonatal period. A genome-wide profiling study in mice found 21 differently expressed miRNAs in hyperoxia-exposed BPD mice. Both miR-30 and miR-133 showed a more than 2-fold increase in BPD mice, compared to control mice, and the expression increased with advancing age, at 2, 7, and 21 post-natal days. 31 An increase of oxygen exposure with the ages might be one possible factor relating to the change in miRNA expression. Our finding concerning Fig. 2 . Receiver operating characteristic curve for the discrimination of bronchopulmonary dysplasia by the 4-microRNA signature model. Fig. 3 . Expression pattern of the 4-microRNA (miRNA) signature in the younger-age and older-age sets in a subsample of 16 infants (7 subjects with BPD and 9 subjects without BPD) with their RNA expression levels examined at both time points. miR-152 and miR30a-3p were down-regulated, and miR-133b and miR-7 were upregulated in the BPD group, compared to the non-BPD group in the older-age set, compared to the younger-age set.
miR-30a-3p down-regulation in preterm infants with BPD was in contrast to the up-regulation observed in the mouse BPD model. 31 Future investigation of the evolution of miRNA expression at various time points after oxygen use may elucidate how oxygen therapy might alter the expression levels of the 4 miRNAs in preterm infants with BPD. In addition to the lung injury caused by oxidative stress, developmental disorders of alveolarization and dysmorphic pulmonary vasculature have recently been recognized as pathology hallmarks of the new form of BPD. 6 While the lung tissue is not readily accessible for investigation of miRNAs in the surviving preterm infants, blood-based expression profiling is increasingly being undertaken as a noninvasive method to investigate BPD biomarkers. It is plausible that these BPD-related expression aberrations of miRNAs in the peripheral mononuclear leukocyte might relate to the pathologic changes of fewer alveolar capillary and dysmorphic pulmonary vasculature in the preterm infants with BPD. The insult to the gas-exchange function may exert its influence on the gene expression of peripheral lymphocytes via cytokines, growth factors, or transmembrane molecules. 43, 44 An intriguing finding from the functional pathway analyses among database-derived target genes for the 4 miRNAs indicated that the 2 most important target genes, NFIB and GLI3, are involved in lung development, such as alveolarization and pulmonary vasculature, consistent with the pathological hallmarks of the new form of BPD. 6, 45 For example, the transcription factors encoded by NFIB genes were highly expressed in embryonic mouse lung and might be involved in fetal lung maturation, 46, 47 and GLI3, a transcription factor of the sonic hedgehog cascade, is critical for the patterning of early lung morphogenesis in mice. 48, 49 Moreover, NFIB-deficient mice die shortly after birth, and their severe lung hypoplasia resembles BPD. 47, 50 In future work the miRNA-target genes must be validated using either exogenous (eg, over-expression of certain miRNAs in lung cell lines to examine the protein expression level of the target genes) or endogenous (eg, manipulation of miRNAs under physiological conditions) miRNA experiments. 51 The Wnt/␤-catenin signaling pathway identified from the canonical biological pathway analysis among the miRNA-targeted genes can regulate airway epithelial differentiation and vascular smooth muscle proliferation in the developing lung. 52 Disruption of the Wnt/␤-catenin signaling pathway in primordial mouse lung results in a failure to form lung buds and thereby arrests proliferation in the vascular smooth muscle of the lungs. 53, 54 Further investigation should examine how the target genes and the 4-miRNA signature modulate the Wnt/␤-catenin signaling pathway in an animal or cell line model of BPD.
The results of this study should be interpreted with some limitations in mind. First, because the number of human miRNAs (n ϭ 365) examined in this study was much less than what is currently available (more than 1,600 to date), further assessment of the miRNAs not included in our experiment is warranted. Second, despite the acceptable discriminative accuracy of the blood-based miRNAs for BPD, these biomarkers might not represent the entire spectrum of regulatory changes in BPD pathophysiology. Direct examination of the lung tissue is needed to clarify the underlying mechanisms. Third, VLBW preterm infants without BPD were treated as the controls in this study. Nevertheless, the individual differences among the subjects with BPD and those without BPD in terms of the growth and nutrition status, neonatal care, and other medical treatments during the neonatal period were not accounted for in this study. Experimental factors such as the miRNA assay conditions may further influence the miRNA expression levels and, hence, the fold-change in relative expression of miRNA when using the data of controls as the reference. Finally, the sample size in this study was relatively small; therefore, future validation of our results in a larger sample is necessary.
Conclusions
In summary, this study demonstrates the potential utility of a mononuclear leukocyte-based miRNA signature as a biomarker for BPD in VLBW preterm infants. As the pathology features of the new form of BPD have been changed to a developmental disorder of the neonatal lung, the identified miRNAs and related target genes in this study provide insight for future investigation of the pathogenesis of BPD in VLBW preterm infants.
